Active Recombinant Human FLT4 protein, Tyr25-Glu775-tagged, Biotinylated

• Cat.No.: FLT4-051H
• Product Overview: Biotinylated Recombinant Human FLT4(Tyr25-Glu775) protein, fused to His/Avi tag at the C-terminus, was expressed in HEK293 cells .

Specification

• Description: VEGFR2 (KDR/Flk-1), VEGFR1 (Flt‑1) and VEGFR3 (Flt‑4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. VEGFR3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGFR3 (Flt‑4). VEGFR3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGFR3 may be important for lymph angiogenesis.
• Source: HEK293 cells
• Species: Human
• Tag: His&Avi
• Predicted N Terminal: Tyr25
• Form: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Bio-activity: The biotin to protein ratio is greater than 0.7 as determined by the HABA assay. Measured by its binding ability in a functional ELISA. When Recombinant Human VEGF-C is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human FLT4 His-tag Avi-tag binds with an ED50 of 15-90 ng/mL.
• Molecular Mass: 115-140 kDa, 72-89 kDa and 60-70 kDa
• Protein length: Tyr25-Glu775
• Endotoxin: <0.10 EU per 1 μg of the protein by the LAL method.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Applications: Bioactivity
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 °C as supplied.1 month, 2 to 8 °C under sterile conditions after reconstitution.3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Reconstitution: Reconstitute at 500 μg/mL in PBS.

Gene Information

• Gene Name: FLT4 fms-related tyrosine kinase 4 [ Homo sapiens ]
• Official Symbol: FLT4
• Synonyms: FLT4; fms-related tyrosine kinase 4; vascular endothelial growth factor receptor 3; PCL; VEGFR3; FLT-4; VEGFR-3; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; fms-like tyrosine kinase 4; tyrosine-protein kinase receptor FLT4; FLT41; LMPH1A
• Gene ID: 2324
• mRNA Refseq: NM_002020
• Protein Refseq: NP_002011
• MIM: 136352
• UniProt ID: P35916

Reviews

09/05/2022

The catalytic activity of FLT4 is very strong, which can significantly improve the selectivity and yield of chemical reactions, and its application potential is great.

09/26/2019

We were reassured that the quality of FLT4 was consistent.

03/23/2019

Using FLT4 for experiments, I can focus more on experimental design and data analysis without worrying about the reproducibility of experimental results.

Q&As

Does FLT4 protein correlate with tumor-related markers?

FLT4 protein is associated with various tumor-related markers such as malignant lymphoma, breast cancer, and lung cancer.

Is there a relationship between FLT4 protein and lymphedema?

FLT4 protein is a key regulator of lymphedema and plays an important role in lymphangiogenesis and lymphatic drainage.

Is FLT4 protein associated with congenital lymphedema?

Yes, mutations in the FLT4 protein can lead to congenital lymphedema, a condition caused by abnormal lymphatic vessel development.

What is the potential of FLT4 protein in cancer treatment?

The protein is considered an important target in anticancer therapy, and inhibition of its activity may reduce tumor angiogenesis and metastasis.

What is the role of FLT4 protein in pulmonary hypertension?

FLT4 protein plays an important role in pulmonary hypertension, and upregulation of its activity may lead to pathological changes such as vascular remodeling and pulmonary artery stenosis.

What is the role of FLT4 protein in angiogenesis?

This is involved in the regulation of angiogenesis and lymphangiogenesis by binding to vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D).